Tilray Faces Fresh Skepticism from Analysts Despite Strong Q2 Revenue

Tilray?s latest quarterly results outperformed revenue expectations, yet the stock faces renewed caution from analysts after a fresh round of ratings changes and target cuts. A notable downgrade came from Wall Street Zen, which moved its rating on Tilray from Hold to Sell on the weekend. The move underscores a cautious tone even as the company demonstrates top-line strength. How do these developments sit with the latest figures and expansion plans?

Key takeaways
- Wall Street Zen: downgrade from Hold to Sell
- Roth MKM: January price target cut from $20 to $10 (rating remains Neutral)
- Q2 fiscal 2026: Net revenue approximately $217.5 million, beating the consensus around $211 million
- United Kingdom: distribution agreement via the German subsidiary CC Pharma with Smartway Pharmaceuticals

Analysts growing more conservative
The Wall Street Zen downgrade is part of a broader mood shift among analysts. Earlier in January, Roth MKM trimmed its target significantly?from $20 to $10?though it kept the rating at Neutral. Looking at the wider consensus, the Street remains cautious; the prevailing view in the sector puts Tilray at Hold, with one Buy and one Sell among the scattered calls.

Quarterly results: strong revenue, mixed earnings
The latest results cover Tilray?s second quarter of fiscal year 2026. Revenue came in stronger than expected, with net sales of about $217.5 million, topping a consensus that hovered around $211 million (roughly $210.95?$211.15 million range).

Earnings were a mixed picture: adjusted earnings per share of -$0.02, in line with expectations. There was an additional metric showing +$0.01 per share, which exceeded the Street estimate of -$0.20. On a GAAP basis, Tilray posted a net loss of -$0.41 per share.

UK expansion via a new distribution partner
Beyond the sentiment shifts, Tilray is pushing ahead with international growth. Its German subsidiary, CC Pharma, finalized a distribution agreement with Smartway Pharmaceuticals to bring medical cannabis products to the United Kingdom. The plan leverages Smartway?s established network to supply pharmacies and hospitals across the UK.

Market context
As of the latest close, Tilray?s market capitalization stood around $875 million. The stock traded over the past year within a range of $3.51 to $23.20 per share.